Tuesday, December 02, 2014 7:37:54 AM
SAINT LAURENT, Quebec, Dec. 2, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx") today announced that its licensing partner Edgemont Pharmaceuticals, LLC ("Edgemont") has exercised its right to extend the license for the exclusive marketing of Forfivo XL® 450 mg tablets.
Under the terms of the extension, Edgemont will retain certain exclusive rights to market and sell Forfivo XL® in the U.S. In exchange, IntelGenx will receive a seven-figure milestone payment. All other financial obligations contained in the license agreement entered into by Edgemont and IntelGenx in February 2012, specifically launch-related and sales milestones, together with the contractual royalty rates on net sales of the product, remain in effect.
"We are very pleased that Edgemont will continue to be the exclusive commercialization partner of Forfivo XL," stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "We have witnessed significant progress in sales of the product during recent months, with monthly sales exceeding $1 million in October and we believe that this growth will continue. We are confident that our partner, Edgemont Pharmaceuticals, has and will continue to make every effort to maximize the potential of Forfivo XL in the U.S."
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.
Recent IGXT News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 07:45:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:00:40 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/15/2024 04:15:15 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 07/08/2024 09:23:06 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/08/2024 09:18:26 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 07/08/2024 06:50:04 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM